UPDATE 1-U.S. approves GSK, Xenoport drug for new use
LONDON, June 7
LONDON, June 7 (Reuters) - GlaxoSmithKline and XenoPort have received approval from the U.S. Food and Drug Administration to sell Horizant to treat post-herpetic neuralgia, the companies said on Thursday.
The medicine is already approved as a treatment for restless legs syndrome. XenoPort will receive a milestone payment of $10 million from GSK following first sales of the drug in its new use.
- Tweet this
- Share this
- Digg this
- CEO in apparent suicide was bitcoin fan, had other issues, too
- Man called Bitcoin's father denies ties, leads LA car chase
- Singapore's megachurches move to export lucrative religion
- Kremlin aide warns U.S. of response if sanctions imposed - RIA
- Exclusive - Pimco's Gross declares El-Erian is 'trying to undermine me'